Literature DB >> 3924420

Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells.

S Kasai, H Arimura, M Nishida, T Suyama.   

Abstract

The relative fibrin-binding, fibrinolytic and fibrinogenolytic properties of single-chain pro-urokinase, an inactive proenzyme form of human urokinase purified from cultured human kidney cells, and urokinase were compared. The affinity of single-chain pro-urokinase for fibrin was much higher than that of urokinase. In Vitro thrombolytic studies showed that single-chain pro-urokinase is approximately three times more potent in fibrinolysis than urokinase and that it does not degrade fibrinogen in the plasma at a concentration, at which complete plasma clot lysis takes place; whereas, urokinase extensively degrades the fibrinogen in the plasma. These specific, potent thrombolytic properties of single-chain pro-urokinase seem to be due to its high affinity for fibrin and to its conversion from the inactive single-chain form to the active two-chain form on the thrombus by the catalytic amount of plasmin generated during coagulation. This single-chain pro-urokinase obtained from human kidney cells by tissue culture should prove advantageous than urokinase in thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924420     DOI: 10.1247/csf.10.151

Source DB:  PubMed          Journal:  Cell Struct Funct        ISSN: 0386-7196            Impact factor:   2.212


  2 in total

1.  Single-nucleotide polymorphism of the urokinase-plasminogen activator gene during aging and transformation of human diploid kidney cell cultures.

Authors:  Safedin H Beqaj; David Post; Jon M Ryan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Sep-Oct       Impact factor: 2.416

2.  Identification of cells responsible for urokinase-type plasminogen activator synthesis and secretion in human diploid kidney cell cultures.

Authors:  Safedin Beqaj; Anuja M Shah; Jon M Ryan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Mar-Apr       Impact factor: 2.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.